PRL-8-53
also PRL 8-53 · PRL-8-53 hydrochloride
PRL-8-53 is a synthetic benzoic acid ester built on a phenethylamine skeleton, with one published human experiment: a double-blind, placebo-controlled test of a single 5 mg oral dose in 47 healthy adults [1]. Recall of a 12-word list a day later rose from 5.16 to 7.37 words in order, with a smaller effect on learning the list and none on visual reaction time or hand steadiness [1]. The result has never been replicated, and the paper's statistics and drug lot both have problems.
One unreplicated 1978 experiment found better word-list recall after a single 5 mg dose; nothing since has confirmed it, and the animal pharmacology is a two-page 1974 note by the same author.

- meta-analysis
- RCT
- trial
- observational
- preclinical / case
- review / patent / other
- retracted
- + Next-day recall of a word list rose from 5.16 to 7.37 of 12 words in one double-blind experiment
- + Largest gains in people who recalled little on placebo and in those over 30
- + No adverse reaction reported by any subject at 5 mg
- − No improvement in visual reaction time or hand steadiness
- − No significant benefit in subjects who already recalled 8 or more words
- − Single experiment by the compound's inventor, never independently replicated
PRL-8-53 is 3-(2-benzylmethylaminoethyl)benzoic acid methyl ester hydrochloride, developed by Nikolaus Hansl of Creighton University. Its human evidence is one paper, received by the journal in 1975 and published in 1978 [1].
Forty-seven healthy adults recruited from the university's faculty and students took a capsule of either 5 mg PRL-8-53 or placebo 2 to 2.5 hours before a serial anticipation test, under double-blind conditions. Each test used a recorded list of 12 one-syllable words, repeated nine times, with the number of correct anticipations scored as acquisition. Subjects later wrote down the words they remembered: the count of words recalled was the gross score, and the count recalled in the right order the discrete score. Only subjects with one drug test and one placebo test were analyzed, by one-tailed t-test [1].
| Measure | Pairs | Placebo | PRL-8-53 | P |
|---|---|---|---|---|
| Acquisition (correct anticipations) | 52 | 59 | 63.4 | < 0.02 |
| 24-hour recall, in order (of 12) | 43 | 5.16 | 7.37 | < 0.001 |
| 24-hour recall, any order | 43 | 5.63 | 7.78 | < 0.001 |
| 1-week recall, in order | 35 | 3.97 | 5.77 | < 0.001 |
| 1-week recall, any order | 35 | 4.14 | 6.06 | < 0.001 |
The authors called the 7.5% acquisition gain borderline and the retention gains highly significant [1].
They then split the sample by how well people did on placebo. Subjects who recalled 6 words or fewer in order at 24 hours on placebo, over 60% of the sample, went from 3.25 to 6.21 words at 24 hours and from 2.28 to 4.68 at one week, and their acquisition improved by 18.7%. Subjects who recalled 8 or more did not improve significantly: acquisition was 72.56 on placebo and 69.38 on drug, 24-hour ordered recall 9.0 and 9.92, and only the 24-hour any-order score reached P < 0.02. The 17 subjects over 30 years old went from 2.42 to 5.35 words at 24 hours and improved 31.4% on acquisition [1].
Visual reaction time and hand steadiness were each slightly better after the drug, neither significantly, and the paper gives no figures for them [1].
The paper says other clinical studies would be reported elsewhere [1]. A 1974 note by Hansl had already claimed clinical trials in over 100 subjects, with better learning and recall of nonsense syllables and better scores on a word completion test, but it gave no doses, designs or numbers [2]. No later human study of PRL-8-53 is indexed in PubMed.
No receptor binding or human mechanistic data have been published. The animal pharmacology comes from two sources by the compound's developer: a two-page 1974 note that reports experiments briefly [2], and the introduction of the 1978 human paper, which summarizes conference abstracts and a patent without presenting data [1].
The 1974 note describes the synthesis and a first screen. On isolated rabbit ileum the compound was a spasmolytic about three times as active as papaverine. At 4 mg/kg it potentiated apomorphine-induced gnawing, a dopamine-dependent behavior. It did not block monoamine oxidase in vitro at 10⁻³ M and, at 20 mg/kg by mouth, did not potentiate methamphetamine in the conditioned avoidance test, the pattern expected of a tricyclic antidepressant. Motor activity was unchanged in rats and slightly reduced in mice at 100 mg/kg [2].
The same note reports learning experiments in Holtzman rats given 10 mg/kg by mouth 1.5 to 2 hours before testing. In what it calls a typical foot-shock experiment, 19 treated rats escaped within the time limit against 13 saline controls (n = 26), and 14 treated rats against 6 controls made the conditioned avoidance response before the shock. In a food-rewarded corridor maze with 50 rats, 16% of controls reached criterion after 4 minutes, against 29% at 10 mg/kg and 40% at 20 mg/kg. The results are called statistically significant, but no tests or P values are given [2].
The 1978 paper adds, without data, that PRL-8-53 produced a cholinergic response in animals, potentiated dopamine, partially inhibited serotonin and reversed reserpine-induced catatonia and ptosis. It also says the compound depressed motor activity in mice and rats (a 50% reduction at 160 mg/kg in mice), did not change the avoidance rate of rats on a continuous avoidance schedule, and produced no amphetamine-like stereotypy at up to 200 mg/kg [1].
The authors' working idea was that memory depends on a balance between transmitter systems, and that a compound with this profile shifts the balance favorably. The human experiment did not test that idea [1].
- Cholinergic signalingactivatesdescribed as producing a cholinergic response in animals; the 1978 paper states this from the author's earlier reports and shows no data [1]unclear
- Dopamine signalingmodulatesunclear
- Serotonin signalingblocksdescribed as causing partial inhibition of serotonin in animals, without data in the paper [1]unclear
Dosing
as studied or commonly reported; not a recommendationDoses below are what studies used or, where marked, what is commonly reported. None is a recommendation.
Oral
- 5 mghealthy adult university faculty and students, word-list learning and recall, against placebosingle dose 2–2.5 hours before the learning sessionhuman study[1]
- 10 mg/kg (human equivalent ≈1.6 mg/kg)
- 10–20 mg/kg (human equivalent ≈1.6–3.2 mg/kg)
- Form
- The trial used capsules holding 5 mg of the hydrochloride salt mixed with magnesium trisilicate as filler; the placebo capsule held magnesium trisilicate alone [1].
- Timing and food
- Taken once, 2 to 2.5 hours before the learning session [1].
- Notes
- Only a single 5 mg dose has been tested in people. No other dose, no repeated dosing and no dose-response comparison has been published [1].
Pharmacokinetics
what the body does with it| Onset | Not measured; the one human experiment gave the capsule 2 to 2.5 hours before testing [1] |
|---|---|
| Metabolism | The authors call the desmethyl compound a metabolite of PRL-8-53 but report no measurements [1] |
Safety
risks and cautions, not medical adviceAll subjects in the human experiment were asked about side effects after a single 5 mg dose, and none reported an adverse reaction. The absence of any worsening in reaction time or hand steadiness was noted by the authors as relevant for a phenethylamine-related compound [1].
Animal toxicity is reported in a few lines. The oral LD50 was 700–800 mg/kg in rats [2] and 860 mg/kg in mice [1]. At 150–200 mg/kg injected intraperitoneally, the compound caused motor tremors and convulsions with leaping and rolling, followed by ataxia, slowed and gasping respiration, cyanosis, diuresis and death [2].
In normotensive dogs, intravenous doses of 1 and 2 mg/kg did not change blood pressure and further doses of 4 and 8 mg/kg caused brief falls, with no change in heart rate. At up to 16 mg/kg the pressor response to epinephrine and the depressor responses to acetylcholine and bradykinin were unaffected [2].
That is the whole published record. There are no repeated-dose human data, no laboratory or cardiovascular measurements in people, and no long-term animal toxicology in the literature.
- One experiment, run by the compound's inventor, with no independent replication in the decades since [1]
- A single 5 mg dose; no dose-response, repeated dosing or pharmacokinetics [1]
- One-tailed t-tests on paired tests, with subgroups defined by the subjects' own placebo scores; low scorers on placebo would be expected to score higher on a second test from regression to the mean alone [1]
- The table counts 52 acquisition pairs from 47 volunteers, so some subjects contributed more than one pair, and fewer pairs have retention scores (43 at 24 hours, 35 at one week) [1]
- The methods describe recall tests at 24 hours and 4 days, while the tables report 24 hours and 1 week [1]
- A note added in proof says the drug lot contained a small amount of the desmethyl compound, which may have contributed to the effect [1]
- The animal pharmacology is a two-page note without statistics, group sizes for most tests or raw data; the cholinergic and serotonin claims appear only in a later summary of conference abstracts and a patent [1][2]
- The clinical trials in over 100 subjects mentioned in 1974 were never published in detail, apart from the 1978 experiment [2]
- What human evidence is there for PRL-8-53?
- One 1978 double-blind experiment in 47 healthy adults. After a single 5 mg oral dose, ordered recall of a 12-word list a day later averaged 7.37 words against 5.16 on placebo; visual reaction time and hand steadiness did not change significantly [1].
- What dose was used in the human study?
- A single 5 mg capsule of the hydrochloride salt, taken 2 to 2.5 hours before the learning session [1].
- Did everyone improve?
- No. Subjects who recalled 8 or more of the 12 words on placebo showed no significant gain on most measures, while those who recalled 6 or fewer roughly doubled their scores [1].
- How does PRL-8-53 work?
- It is not known. The 1978 paper says earlier animal work showed a cholinergic response, potentiation of dopamine and partial inhibition of serotonin, without data [1]. A 1974 note reports that it potentiated apomorphine-induced gnawing and did not block monoamine oxidase [2]. No receptor target has been published.
- Is there animal evidence that PRL-8-53 improves learning?
- One 1974 note. Rats given 10 mg/kg by mouth did better on foot-shock escape and conditioned avoidance tests, and 29% and 40% of rats given 10 and 20 mg/kg reached criterion in a maze against 16% of controls. No statistical tests are reported [2].
References
entry last reviewed 2026-10-11- [1]PRL-8-53: enhanced learning and subsequent retention in humans as a result of low oral doses of new psychotropic agent.Hansl NR, Mead BTPsychopharmacology (Berl) 1978RCT · humanPMID 418433◌ unreviewed
- [2]A novel spasmolytic and CNS active agent: 3-(2-benzylmethylamino ethyl) benzoic acid methyl ester hydrochloride.Hansl NRExperientia 1974other · animalPMID 4824605◌ unreviewed
- [3]A simple practice guide for dose conversion between animals and human.Nair AB, Jacob SJ Basic Clin Pharm 2016reviewPMID 27057123◌ unreviewed